CSBio CSBio

X
[{"orgOrder":0,"company":"AOP Orphan","sponsor":"Eagle Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$5.0 million","newsHeadline":"Eagle Announces Licensing Agreement with AOP Orphan for Landiolol","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase III","country":"AUSTRIA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"AOP Orphan"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The Company will support the submission of a new drug application to the U.S. FDA seeking approval for Landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter.

            Lead Product(s): Landiolol Hydrochloride

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: LDLL600

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eagle Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: $5.0 million

            Deal Type: Licensing Agreement August 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY